Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cytokinetics (NQ: CYTK )

38.02 +0.30 (+0.78%)
Streaming Delayed Price Updated: 12:09 PM EDT, Jun 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cytokinetics

< Previous 1 2 3 4 Next >
What 20 Analyst Ratings Have To Say About Cytokinetics
 
Via Benzinga
18 Analysts Have This to Say About Cytokinetics
 
Via Benzinga
Cytokinetics: Q1 Earnings Insights
 
Via Benzinga
Analyst Ratings for Cytokinetics
 
Via Benzinga
Analyst Expectations for Cytokinetics's Future
 
Via Benzinga
Cytokinetics Plans To Discontinue Late-Stage ALS Trial Due To Futility
Cytokinetics Incorporated (NASDAQ: CYTK) announced that the Data Monitoring Committee (DMC) for COURAGE-ALS recently convened to conduct the second planned interim analysis of this Phase 3 clinical... 
Via Benzinga
Analyst Ratings for Cytokinetics
 
Via Benzinga
Cytokinetics Posts Aficamten Data In Patients With Thickened Heart Muscle
 
Via Benzinga
FDA Rejects Cytokinetics' Heart Failure Treatment Candidate
 
Via Benzinga
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
Cytokinetics's Earnings: A Preview
 
Via Benzinga
Analyst Ratings for Cytokinetics
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 17, 2023
 
Via Benzinga
A Patent Cliff Is Coming For Bristol — Can Billions In New Products Fill The Gap?
The company's biggest moneymakers are soon to lose patent protection. 
Via Investor's Business Daily
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
Analyst Ratings for Cytokinetics
 
Via Benzinga
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Biopharma stocks were not immune to the broader market downturn seen for much of 2022. 
Via Benzinga
Tesla To $175? Here Are 10 Other Price Target Changes For Friday
Oppenheimer cut CarMax, Inc. (NYSE: KMX) price target from $100 to $75. . Oppenheimer analyst Brian Nagel maintained an Outperform rating on the stock. CarMax shares fell 1.3% to $56.47 in pre-market... 
Via Benzinga
Expert Ratings for Cytokinetics
 
Via Benzinga
What 7 Analyst Ratings Have To Say About Cytokinetics
 
Via Benzinga
Cytokinetics AdComm Outcome Might Be Blessing In Disguise, This Analyst Said
 
Via Benzinga
FDA Adcomm Gives Thumbs Down To Cytokinetics' Heart Failure Candidate
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2022
 
Via Benzinga
REV Group, Avidity Biosciences And Some Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. 
Via Benzinga
Why Cytokinetics Is Soaring After A 'Bruising' FDA Meeting For Its Heart Drug
The FDA's experts voted 3-8 against the Cytokinetics heart-failure drug. 
Via Investor's Business Daily
Top Stories Today: Jack Dorsey Not Exactly Impressed With Elon Musk's Twitter; Binance Sees $3B Outflow In 7 Days..
Benzinga 
Via Benzinga
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%. 
Via Benzinga
Cytokinetics CEO: Why It's OK Not Being An Overnight Success
The company hopes to come out next year with at least one heart-failure drug. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
Upgrades 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.